Brii Biosciences Limited (BRII-B) disclosed that it repurchased 42,000 ordinary shares on 11 November 2026 through on-market transactions on the Hong Kong Stock Exchange. The repurchase was executed at prices ranging from HKD 1.045 to HKD 1.055 per share, representing a volume-weighted average cost of HKD 1.0482 and an aggregate outlay of HKD 0.04 million.
Following the transaction: • Issued shares (excluding treasury shares) decreased by 0.0058 % to 719.51 million. • Treasury shares increased to 16.34 million. • Total issued share capital remained unchanged at 735.86 million shares, as the repurchased stock is being held in treasury and has not been cancelled.
The buyback forms part of the mandate approved on 16 June 2026, which allows BRII-B to repurchase up to 72.19 million shares. Cumulative repurchases under this mandate now stand at 3.62 million shares, equivalent to 0.50 % of the issued share base as at the authorisation date.
Under Hong Kong Listing Rule 10.06, the company is restricted from issuing new shares or disposing of treasury shares for 30 days after the repurchase, setting a moratorium period through 11 December 2026.
Comments